Navigation Links
Use of Vitamin K Antagonists in the Treatment of Atrial Fibrillation is Driven by the Availability of an Oral Formulation, Cost and Widespread Inclusion on Guidelines and Formularies

MALVERN, Pa., Dec. 15, 2010 /PRNewswire/ -- Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that, in the treatment of atrial fibrillation, surveyed European cardiologists indicate that use of vitamin K antagonists, as a class, is primarily driven by the availability of an oral formulation, overall low cost and widespread inclusion on European medical society guidelines and hospital formularies. Vitamin K antagonists and low molecular weight heparins are the most commonly used anticoagulants across physician specialties in Europe.

"Orally administered vitamin K antagonists tend to dominate prescribing in both in-patient and discharge therapy setting, while low molecular weight heparins are more frequently used in the in-patient setting because of their injectable formulation," said AMR Analyst James Andersen.

The analysis can be found in Hospital Insight Series: Anticoagulants—Stroke Prevention in Atrial Fibrillation (Europe) which will publish later this month. The report analyzes the use of anticoagulants in atrial fibrillation using AMR's comprehensive and highly detailed clinical data in conjunction with primary research and extensive understanding of the market. This report contains European data and examines the reasons behind cardiologists' product preferences, factors driving anticoagulant prescribing patterns and physician receptivity to emerging treatments.

About AMRAMR ( serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Decision Resources, Inc.Christopher Comfort781-296-2597

SOURCE Arlington Medical Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ChromaDex Partners With Kappa Bioscience to Provide Quality Control Methods, Tools and Services for Vitamin K2
2. FDA Cautions on Accurate Vitamin D Supplementation for Infants
3. Upsher-Smith Introduces New Formulation of PreNexa® Prenatal Vitamins
4. Mission Pharmacal Launches New Vitamin B6-Rich Prescription Prenatal Vitamin, CitraNatal(R) B-Calm
5. Upsher-Smith Announces New Formulation of PreNexa(R) Prenatal Vitamins
6. New Research Shows a Vitamin/Nutriceutical Formulation Improves Memory and Cognitive Performance in Community-Dwelling Adults
7. Vitamin E Improves NASH
8. FDA: Procter & Gamble Unlawfully Marketing Two Vicks Cold and Flu Medicines Containing Vitamin C
9. VitaminSpice Appoints Dr. Richard F. Seelig as Director
10. July 2009 Mayo Clinic Womens HealthSource Highlights Food Storage Safety, Energy Therapies and Vitamins and Minerals
11. Study Suggests Vitamin D Screening and Appropriate Supplementation Indicated for All Cancer Patients
Post Your Comments:
(Date:11/26/2015)... WILMINGTON, North Carolina , 26 november ... Laboratories, Inc. (AAIPharma/CML) kondigt de geplande investering ... de uitbreiding van de laboratoria en het ... . De uitbreiding zal resulteren in ... waarmee wordt voldaan aan de groeiende behoeften ...
(Date:11/26/2015)... , November 26, 2015 3D bioprinting ... 2022, according to a new report by Grand View Research ... Disease (CKD) which demands kidney transplantation is expected to boost ... effective substitute for organ transplantation. --> 3D bioprinting ... 2022, according to a new report by Grand View Research ...
(Date:11/26/2015)... , November 26, 2015 ... Juntendo universitetssjukhus ser potential att använda ... magnetresonansbilder (MR-bilder) för patienter med multipel ... ett forskningsavtal med SyntheticMR AB för att ... forskningsprojekt på sjukhuset. Med SyMRI kan man ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... WorldCare International, ... in the 61st annual Employee Benefits Conference. The Employee Benefits Conference was hosted ... 8th through Wednesday, November 11th, 2015. The conference was held at the Hawaii ...
(Date:11/26/2015)... , ... November 26, 2015 , ... Indosoft Inc., developer ... of an application server to improve system efficiency and reliability. , The new Q-Suite ... of these standards, the system avoids locking itself into a specific piece of software ...
(Date:11/25/2015)... ... November 25, 2015 , ... The holiday ... dish and pleasing the palates of attendees is of the utmost importance. Whether ... a seasonal get-together, give these recipes a try this holiday season. , Turkey ...
(Date:11/25/2015)... ... November 25, 2015 , ... TyloHelo ... parts and accessories. , Sauna accessories help improve the bather experience in the ... From basic styles for the purist looking for simplicity in design to accessories ...
(Date:11/25/2015)... ... 25, 2015 , ... On November 10, 2015, Bohrer Brady, LLC filed a ... behalf of a home health care worker who provided companionship services for the elderly, ... workers employed by Humana, Inc., Humana at Home, Inc., and SeniorBridge Family Companies (CT), ...
Breaking Medicine News(10 mins):